OLMA Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -380280%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Altimmune, Inc.'s return on equity of -56.24%.

Olema Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 32.06%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.88 which suggests that it could grow by 249.8%. Given that Altimmune, Inc. has higher upside potential than Olema Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Olema Pharmaceuticals, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.870, which suggesting that the stock is 86.967% more volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $5K. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Altimmune, Inc.'s net income of -$19M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 21,107.47x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of -259.95%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Insmed, Inc.'s return on equity of -193.23%.

Olema Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 32.06%. On the other hand Insmed, Inc. has an analysts' consensus of $222.78 which suggests that it could grow by 8.65%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Insmed, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.870, which suggesting that the stock is 86.967% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Insmed, Inc.'s net income of -$370M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 87.26x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of 21.32%. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Pfizer Inc.'s return on equity of 10.84%.

Olema Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 32.06%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.870, which suggesting that the stock is 86.967% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.69% to investors and pays a quarterly dividend of $0.43 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus 2.34x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Replimune Group, Inc. has a net margin of -- compared to Olema Pharmaceuticals, Inc.'s net margin of --. Olema Pharmaceuticals, Inc.'s return on equity of -45.61% beat Replimune Group, Inc.'s return on equity of -82.53%.

Olema Pharmaceuticals, Inc. has a consensus price target of $36.50, signalling upside risk potential of 32.06%. On the other hand Replimune Group, Inc. has an analysts' consensus of $12.57 which suggests that it could grow by 19.39%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Replimune Group, Inc..

Olema Pharmaceuticals, Inc. has a beta of 1.870, which suggesting that the stock is 86.967% more volatile than S&P 500. In comparison Replimune Group, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.125%.

Olema Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Replimune Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Olema Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Replimune Group, Inc. pays out -- of its earnings as a dividend.

Olema Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Replimune Group, Inc. quarterly revenues of --. Olema Pharmaceuticals, Inc.'s net income of -$42.2M is higher than Replimune Group, Inc.'s net income of -$83.1M. Notably, Olema Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Replimune Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Olema Pharmaceuticals, Inc. is -- versus -- for Replimune Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.